Quick Answer
GALECTIN THERAPEUTICS INC reported Cash And Cash Equivalents At Carrying Value of $17.72 million for the year ending 2025.
- GALECTIN THERAPEUTICS INC showed an increase of +17.2% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from GALECTIN THERAPEUTICS INC's annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), GALECTIN THERAPEUTICS INC's Cash And Cash Equivalents At Carrying Value has grown by 6,959.8%.
- Historical annual values: Fiscal year 2025: $17.72 million | Fiscal year 2024: $15.12 million | Fiscal year 2023: $25.66 million | Fiscal year 2022: $18.59 million | Fiscal year 2021: $39.65 million | Fiscal year 2020: $27.14 million | Fiscal year 2019: $47.48 million | Fiscal year 2018: $8.25 million | Fiscal year 2017: $3.05 million | Fiscal year 2016: $15.36 million | Fiscal year 2015: $25.85 million | Fiscal year 2014: $29.13 million | Fiscal year 2013: $10.49 million | Fiscal year 2012: $9.36 million | Fiscal year 2011: $6.40 million | Fiscal year 2010: $5.89 million | Fiscal year 2009: $251.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: